A detailed history of Nuveen Asset Management, LLC transactions in Repligen Corp stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 335,104 shares of RGEN stock, worth $53.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
335,104
Previous 338,351 0.96%
Holding current value
$53.9 Million
Previous $42.7 Million 16.92%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.79 - $167.35 $388,958 - $543,385
-3,247 Reduced 0.96%
335,104 $49.9 Million
Q2 2024

Aug 09, 2024

SELL
$120.0 - $182.95 $24 Million - $36.6 Million
-200,079 Reduced 37.16%
338,351 $42.7 Million
Q1 2024

May 13, 2024

SELL
$170.78 - $208.42 $458,885 - $560,024
-2,687 Reduced 0.5%
538,430 $99 Million
Q4 2023

Feb 14, 2024

BUY
$114.17 - $185.35 $19.1 Million - $31 Million
166,998 Added 44.64%
541,117 $97.3 Million
Q3 2023

Nov 14, 2023

BUY
$138.78 - $176.51 $22.2 Million - $28.2 Million
159,984 Added 74.71%
374,119 $59.5 Million
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $1.36 Million - $1.77 Million
9,825 Added 4.81%
214,135 $30.3 Million
Q1 2023

May 15, 2023

SELL
$154.26 - $198.1 $1.68 Million - $2.16 Million
-10,915 Reduced 5.07%
204,310 $34.4 Million
Q4 2022

Feb 14, 2023

SELL
$162.42 - $220.56 $8.1 Million - $11 Million
-49,876 Reduced 18.81%
215,225 $36.4 Million
Q3 2022

Nov 14, 2022

SELL
$160.42 - $256.21 $1.61 Million - $2.58 Million
-10,061 Reduced 3.66%
265,101 $49.6 Million
Q2 2022

Aug 15, 2022

SELL
$140.68 - $188.02 $1.4 Million - $1.87 Million
-9,949 Reduced 3.49%
275,162 $44.7 Million
Q1 2022

May 16, 2022

BUY
$161.19 - $257.96 $10.1 Million - $16.2 Million
62,727 Added 28.21%
285,111 $53.6 Million
Q4 2021

Feb 14, 2022

SELL
$247.59 - $304.47 $6.55 Million - $8.05 Million
-26,444 Reduced 10.63%
222,384 $58.9 Million
Q3 2021

Nov 12, 2021

SELL
$194.77 - $324.21 $9.26 Million - $15.4 Million
-47,568 Reduced 16.05%
248,828 $71.9 Million
Q2 2021

Aug 16, 2021

SELL
$165.87 - $220.95 $166,533 - $221,833
-1,004 Reduced 0.34%
296,396 $59.2 Million
Q1 2021

May 17, 2021

SELL
$180.37 - $226.26 $914,295 - $1.15 Million
-5,069 Reduced 1.68%
297,400 $57.8 Million
Q4 2020

May 17, 2021

SELL
$148.08 - $206.57 $1.83 Million - $2.56 Million
-12,390 Reduced 3.94%
302,469 $58 Million
Q4 2020

Feb 16, 2021

BUY
$148.08 - $206.57 $12.3 Million - $17.1 Million
82,748 Added 35.65%
314,859 $60.3 Million
Q3 2020

Nov 16, 2020

BUY
$122.51 - $158.27 $6.61 Million - $8.54 Million
53,947 Added 30.28%
232,111 $34.2 Million
Q2 2020

Aug 14, 2020

SELL
$94.33 - $140.48 $22.4 Million - $33.3 Million
-236,990 Reduced 57.08%
178,164 $22 Million
Q1 2020

May 14, 2020

BUY
$84.96 - $109.14 $2.07 Million - $2.65 Million
24,310 Added 6.22%
415,154 $40.1 Million
Q4 2019

Feb 14, 2020

BUY
$73.84 - $93.08 $6.22 Million - $7.84 Million
84,232 Added 27.47%
390,844 $36.2 Million
Q3 2019

Nov 14, 2019

SELL
$76.65 - $95.51 $4.28 Million - $5.33 Million
-55,796 Reduced 15.4%
306,612 $23.5 Million
Q2 2019

Aug 15, 2019

BUY
$54.2 - $85.95 $18.1 Million - $28.8 Million
334,696 Added 1207.77%
362,408 $31.1 Million
Q1 2019

May 14, 2019

SELL
$49.45 - $62.8 $192,657 - $244,668
-3,896 Reduced 12.33%
27,712 $1.64 Million
Q4 2018

Feb 14, 2019

SELL
$48.26 - $68.88 $949,805 - $1.36 Million
-19,681 Reduced 38.37%
31,608 $1.67 Million
Q3 2018

Nov 13, 2018

SELL
$46.8 - $58.97 $412,635 - $519,938
-8,817 Reduced 14.67%
51,289 $2.84 Million
Q2 2018

Aug 14, 2018

BUY
$35.26 - $47.04 $1.37 Million - $1.83 Million
38,860 Added 182.91%
60,106 $2.83 Million
Q4 2017

Feb 14, 2018

BUY
$32.53 - $38.92 $103,868 - $124,271
3,193 Added 17.69%
21,246 $0
Q3 2017

Nov 14, 2017

BUY
$36.98 - $46.06 $667,599 - $831,521
18,053
18,053 $692,000

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $8.93B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.